Reuters logo
Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln
September 5, 2017 / 8:43 PM / in 3 months

Novo Nordisk settles U.S. probe over diabetes drug for $58.7 mln

Sept 5 (Reuters) - Novo Nordisk will pay $58.7 million to resolve claims that the drugmaker’s sales staff downplayed the importance of a warning about cancer risks on its diabetes medication Victoza’s label, the U.S. Justice Department said on Tuesday. (Reporting by Nate Raymond in Boston; Editing by Phil Berlowitz)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below